Efficacy of Direct-acting Antivirals to Improve Clinical Condition, Fibrosis, and Liver Function in Liver Transplant Recipients Infected by Hepatitis C
- 1 January 2019
- journal article
- conference paper
- Published by Elsevier in Transplantation Proceedings
- Vol. 51 (1) , 74-76
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Long‐term follow‐up of ribavirin‐free DAA‐based treatment in HCV recurrence after orthotopic liver transplantationLiver International, 2017
- ELITA consensus statements on the use of DAAs in liver transplant candidates and recipientsJournal of Hepatology, 2017
- Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation CohortTransplantation Proceedings, 2016
- Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infectionLiver Transplantation, 2016
- Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrenceHepatology, 2016
- Current Management of Hepatitis C VirusClinics in Liver Disease, 2015
- Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplantClinical Transplantation, 2015
- Triple Therapy Using Direct-Acting Agents for Recurrent Hepatitis C After Liver Transplantation: A Single-Center ExperienceTransplantation Proceedings, 2015
- Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipientsLiver Transplantation, 2015